Treatment of essential thrombocythemia with anagrelide

M. N. Silverstein, Ayalew Tefferi

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Essential thrombocythemia (ET), the most common of the chronic myeloproliferative disorders, is characterized by thrombotic and hemorrhagic complications. Thrombotic complications predominate, endangering especially the older population and those with prior history of thrombotic episodes. However, because the life expectancy of ET patients is generally of normal length, caution must be exercised in treating these patients, and the complications of treatment must be weighed against the complications of the disease. Historically, most drugs used in the treatment of ET, such as alkylating agents and radiophosphorus, were carcinogenic themselves. Even hydroxyurea has recently come under investigation for its long-term mutagenicity. The newest drug, anagrelide, approved in March 1997 specifically for ET, appears to be safe and well tolerated.

Original languageEnglish (US)
Pages (from-to)23-25
Number of pages3
JournalSeminars in Hematology
Volume36
Issue numberSUPPL. 2
StatePublished - 1999

Fingerprint

Essential Thrombocythemia
Myeloproliferative Disorders
Hydroxyurea
Alkylating Agents
Therapeutics
Life Expectancy
Pharmaceutical Preparations
anagrelide
Population

ASJC Scopus subject areas

  • Hematology

Cite this

Treatment of essential thrombocythemia with anagrelide. / Silverstein, M. N.; Tefferi, Ayalew.

In: Seminars in Hematology, Vol. 36, No. SUPPL. 2, 1999, p. 23-25.

Research output: Contribution to journalArticle

Silverstein, MN & Tefferi, A 1999, 'Treatment of essential thrombocythemia with anagrelide', Seminars in Hematology, vol. 36, no. SUPPL. 2, pp. 23-25.
Silverstein, M. N. ; Tefferi, Ayalew. / Treatment of essential thrombocythemia with anagrelide. In: Seminars in Hematology. 1999 ; Vol. 36, No. SUPPL. 2. pp. 23-25.
@article{809d245f8c8b4cc0a1227eafc31d19e4,
title = "Treatment of essential thrombocythemia with anagrelide",
abstract = "Essential thrombocythemia (ET), the most common of the chronic myeloproliferative disorders, is characterized by thrombotic and hemorrhagic complications. Thrombotic complications predominate, endangering especially the older population and those with prior history of thrombotic episodes. However, because the life expectancy of ET patients is generally of normal length, caution must be exercised in treating these patients, and the complications of treatment must be weighed against the complications of the disease. Historically, most drugs used in the treatment of ET, such as alkylating agents and radiophosphorus, were carcinogenic themselves. Even hydroxyurea has recently come under investigation for its long-term mutagenicity. The newest drug, anagrelide, approved in March 1997 specifically for ET, appears to be safe and well tolerated.",
author = "Silverstein, {M. N.} and Ayalew Tefferi",
year = "1999",
language = "English (US)",
volume = "36",
pages = "23--25",
journal = "Seminars in Hematology",
issn = "0037-1963",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Treatment of essential thrombocythemia with anagrelide

AU - Silverstein, M. N.

AU - Tefferi, Ayalew

PY - 1999

Y1 - 1999

N2 - Essential thrombocythemia (ET), the most common of the chronic myeloproliferative disorders, is characterized by thrombotic and hemorrhagic complications. Thrombotic complications predominate, endangering especially the older population and those with prior history of thrombotic episodes. However, because the life expectancy of ET patients is generally of normal length, caution must be exercised in treating these patients, and the complications of treatment must be weighed against the complications of the disease. Historically, most drugs used in the treatment of ET, such as alkylating agents and radiophosphorus, were carcinogenic themselves. Even hydroxyurea has recently come under investigation for its long-term mutagenicity. The newest drug, anagrelide, approved in March 1997 specifically for ET, appears to be safe and well tolerated.

AB - Essential thrombocythemia (ET), the most common of the chronic myeloproliferative disorders, is characterized by thrombotic and hemorrhagic complications. Thrombotic complications predominate, endangering especially the older population and those with prior history of thrombotic episodes. However, because the life expectancy of ET patients is generally of normal length, caution must be exercised in treating these patients, and the complications of treatment must be weighed against the complications of the disease. Historically, most drugs used in the treatment of ET, such as alkylating agents and radiophosphorus, were carcinogenic themselves. Even hydroxyurea has recently come under investigation for its long-term mutagenicity. The newest drug, anagrelide, approved in March 1997 specifically for ET, appears to be safe and well tolerated.

UR - http://www.scopus.com/inward/record.url?scp=0032926216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032926216&partnerID=8YFLogxK

M3 - Article

C2 - 9930554

AN - SCOPUS:0032926216

VL - 36

SP - 23

EP - 25

JO - Seminars in Hematology

JF - Seminars in Hematology

SN - 0037-1963

IS - SUPPL. 2

ER -